Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel
FDA seeks input on the "slim margin" of efficacy and the adequacy of safety data for Arena's obesity drug.
FDA seeks input on the "slim margin" of efficacy and the adequacy of safety data for Arena's obesity drug.